• Genetic Analysis won a Canadian patent covering an in vitro diagnostic to identify IBS patients more likely to respond to fecal microbiota transplantation.
• Test uses gut microbiota signatures to separate likely responders from non-responders, aiming to support treatment selection in IBS.
• Patent protection in Canada runs through 2037, strengthening the company’s companion-diagnostics intellectual property position.
• IBS affects an estimated 5%-10% of the global population; annual US direct and indirect costs are estimated at about USD 30 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genetic Analysis AS published the original content used to generate this news brief via Cision (Ref. ID: 202609220200BITN____UKPR__EN_20260921-BIT-2991-0) on September 22, 2026, and is solely responsible for the information contained therein.